REFERENCE FILE
Bremelanotide
Read the record, then work through the questions.
Reference details
Status as of
- Regulatory category
- Approved product
- Evidence category
- Randomized evidence
- Mechanism
- Melanocortin-receptor agonist.
- Evidence
- Randomized trials.
- Limitations
- Exclude medical, relationship and drug causes; not performance enhancement.
- Safety
- Uncontrolled hypertension or known cardiovascular disease: contraindicated.
- Formulation and route
- Subcutaneous injection.
- Approval scope
- Vyleesi: eligible premenopausal women with distressing acquired generalized low-desire disorder.
A SECOND LOOK
A question to carry into the reading
For this bremelanotide profile, keep track of what you cannot find as carefully as what you can. When a source presents a result, look for an explanation of which observations were available and how unavailable information was handled. If that explanation is absent from the material you can access, describe the gap precisely. Do not silently replace “I could not locate this information” with a statement about what did or did not happen. Your notes can distinguish a missing passage, an unanswered reporting question, and information that the source explicitly says was unavailable. Each leaves a different task for a follow-up conversation.
Questions to keep beside the page
- Does the source explain which observations were available for the reported result?
- What does it say about information that was unavailable or left out?
- Am I recording a documented absence or simply something I could not locate?
Sources for this file
- VYLEESINLM · Checked
- Kingsberg trialsPubMed · Checked
FROM THE REFERENCE DESK